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Craniopharyngiomas are epithelial tumors that typically arise in the suprasellar region of the
brain1. Patients experience substantial clinical sequelae both from extension of the tumors
and from therapeutic interventions which damage the optic chiasm, the pituitary stalk, and
the hypothalamic area2–4. Using whole exome sequencing we identified mutations in beta-
catenin (CTNNB1) in nearly all adamantinomatous craniopharyngiomas (11/12; 92%) and
recurrent mutations in BRAF (V600E) in all papillary craniopharyngiomas (3/3; 100%).
Targeted genotyping revealed BRAF V600E in 95% of papillary craniopharyngiomas (36 of
39 tumors) and CTNNB1 mutation in 96% of adamantinomatous craniopharyngiomas (51 of
53 tumors). The CTNNB1 and BRAF mutations were clonal in each tumor subtype and no
other recurrent mutations or genomic aberrations were detected in either subtype.
Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually
exclusive and clonal. These findings have important implications for the diagnosis and
treatment of these neoplasms.
Craniopharyngiomas occur at an average age-adjusted incidence rate of 0.18 per 100,0005.
There are two main subtypes of craniopharyngiomas – the adamantinomatous form that is
more common in children and the papillary form that predominantly occurs in adults.
Located in or above the sella turcica, craniopharyngiomas grow adjacent to the optic chiasm
and often extend to involve the hypothalamus, cranial nerves, the ventricular system, visual
pathways and major blood vessels at the base of the brain. Curative surgery is exceedingly
difficult6 and resection can contribute to complications. The spectrum of complications
include visual defects, severe headaches, pan-hypopituitarism, impaired intellectual function
and wide-ranging hypothalamic dysfunction leading to sleep disorders7, abnormal thermo-
regulation, and diabetes insipidus as well as to hyperphagia and uncontrollable obesity2–4.
Aptly, Harvey Cushing, the father of neurosurgery, who introduced the term
“craniopharyngioma” declared them “the most formidable of intracranial tumors8,9.”
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and this has hampered the development of systemic therapies for this tumor. Mutations in
exon 3 of beta-catenin (CTNNB1), which encodes a degradation targeting motif, have been
described in adamantinomatous craniopharyngiomas, occurring in 60–75% of patients in
most published series10–12. However, mutations that drive the growth of papillary
craniopharyngiomas have not been identified. To that effect, we performed massively
parallel sequencing of 15 craniopharyngiomas from both subtypes and targeted genotyping
in samples from 95 additional patients.
We first used whole exome sequencing to analyze the DNA from a discovery cohort of
adamantinomatous (n=12) and papillary craniopharyngiomas (n=3) (Supplementary Table
1). As craniopharyngiomas are often heterogeneous tumors with nests of tumor cells
interspersed between large amounts of reactive tissue and stromal cells, we expected
mutations to have low allelic fractions (i.e. the mutations might only be found in a small
subset of the sequenced cells due to substantial contamination by normal cells). Thus, we
analyzed the sequencing data with a recently described method – MuTect – that uses a
Bayesian classifier to identify somatic mutations with very low allelic fractions coupled with
filters that provide high specificity13.
In consonance with the benign histology of these tumors, we identified only a relatively
small number of nonsynonymous somatic mutations in both craniopharyngioma subtypes
when compared to large cohorts of other tumor types14 (Fig. 1). The nonsynonymous
mutation rate of 0.9/MB in the craniopharyngioma samples was similar to that found in a
number of pediatric tumors as well as low grade tumors in adults such as WHO grade I
meningioma15 (Fig. 1). 58% of the mutations were cytosine to thymidine at CpG
dinucleotides which is consistent with spontaneous deamination and not a carcinogen-
induced process (Fig. 1)14. As anticipated, the allelic fraction for many of the mutations was
very low (median 3%; range 0.96–48%).
The most frequently mutated gene was CTNNB1, present in 11 of 12 adamantinomatous
craniopharyngiomas (Fig. 2; Supplementary Tables 2–4). These events overlapped with
mutations previously described in this tumor type and were found exclusively in exon 310,12.
In addition, adamantinomatous craniopharyngiomas harbored isolated mutations in genes
that have previously been implicated in cancer (Fig. 2). We identified mutations in genes
listed in the Cancer Gene Census16 that are involved in transcriptional regulation (BCOR,
CRTC3, MITF and PRDM1) and epigenetic regulation (KDM5A and SMARCA4) as well as
DNA repair (BRCA2) (Fig. 2). Additional mutations were detected in genes not listed in the
Cancer Gene Census but with described roles in cancer including genes involved in
chromatin remodeling and regulation of transcription (including ASCC2, KAT5, PIWIL1,
SIN3A, SMC1A), cell cycle and DNA repair (including ATR, BARD1, CDC25B, HBP1,
RBBP8, RTEL1) and cell adhesion (ITGA3, PKD1, PKD1L1, PODN, ROCK1, RPTN)16.
Many of these, however, may be ‘passenger’ mutations that do not contribute to tumor
initiation or progression.
All three of the papillary craniopharyngiomas in our discovery set harbored mutations (c.
1799T>A) in the well-established oncogene BRAF (V600E) that have been shown to
constitutively activate this serine-threonine kinase that regulates MAP kinase/ERK signaling
and affects cell division and differentiation (Fig. 2). None of the three papillary
craniopharyngiomas had mutations in CTNNB1. Although two of these samples were
resected from adults (31 and 52 years old), one of the samples was from a rare papillary
craniopharyngioma that occurred in a child (9 years old) suggesting a similar pathogenesis
between pediatric and adult papillary craniopharyngiomas. In these tumors, we did not
identify mutations in other genes listed in the Cancer Gene Census but did note isolated
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remodeling factors (CHD5, CHD6)17 and cell adhesion molecules (CDH26, PTPRT)18, and
one (KIAA1549) that is fused to BRAF in most cases of pilocytic astrocytoma19,20. These
mutations, like some of those found in adamantinomatous craniopharyngiomas, may also be
‘passenger’ mutations.
MutSig14 was used to analyze the list of mutations identified in our discovery cohort of 15
cases to identify genes that are significantly mutated. Although our cohort is small compared
to those from other genomic studies14 (Fig. 1), the prevalence of mutations in CTNNB1 and
BRAF was so high that these mutations were readily detected as statistically significant (Fig.
2).
To validate our findings, we used targeted genotyping approaches to analyze an additional
98 craniopharyngioma samples (from 95 different patients) for mutations in the most
commonly mutated genes in our discovery cohort – BRAF and CTNNB1. We also performed
immunohistochemistry (IHC) using an antibody (VE1) that selectively recognizes the BRAF
V600E mutant epitope and not the wild-type epitope from BRAF21. In addition, we
evaluated the activation status of beta-catenin using an antibody that allowed us to detect
nuclear (activated) and membranous (inactivated) beta-catenin12. In total, our validation
cohort consisted of 39 papillary craniopharyngioma tumors from 36 different patients and 59
adamantinomatous craniopharyngioma tumors, each from different patients (Supplementary
Table 1). While CTNNB1 mutations were detected in the adamantinomatous
craniopharyngioma samples (51 of 53 samples, 96%), none of these samples harbored BRAF
mutations (neither V600E, D, L, M nor K). Cytoplasmic and nuclear beta-catenin was
identified by IHC in all of the adamantinomatous samples tested but beta-catenin was
exclusively localized to the cytoplasmic membrane in all papillary craniopharyngioma
samples tested (Supplementary Table 1, Fig. 3). Remarkably, by targeted genotyping and
IHC we detected V600E mutations in 34 of the 36 patients with papillary
craniopharyngiomas (94.4%) (Supplementary Table 1).
The allelic fraction of mutations (including those in BRAF and CTNNB1) in our whole
exome data was low (Fig. 2a, middle panel, Supplementary Table 2). This raised the
possibility of genetic heterogeneity in our tumor samples. To assess this, we used a recently
developed computational method (see Methods section) that corrects for tumor purity and
estimates the fraction of cancer cell nuclei that harbor a particular mutation (cancer cell
fraction; CCF). Although these methods demonstrated that most of the somatic mutations
identified in our samples were indeed subclonal, we found that the BRAF and CTNNB1
mutations were clonal (i.e. present in all tumor cells) in the analyzed samples (Fig. 2a upper
panel, Fig. 4a and Supplementary Table 2-column BB).
To further validate our analysis of intra-tumor heterogeneity, we reviewed the pattern and
distribution of BRAF staining in the craniopharyngioma samples (Supplementary Table 1).
Using the BRAF V600E selective antibody, we did not detect BRAF V600E in the
adamantinomatous craniopharyngioma samples (Supplementary Table 1) nor in two of the
papillary craniopharyngioma samples with wild type BRAF that we tested (Fig. 4b). In the
genetically confirmed BRAF V600E mutant samples, however, we observed widespread
immunoreactivity across the tumor cell population. In these samples, lymphocytes and
stromal cells of the fibrovascular core of the tumors were not immunoreactive, but the
squamopapillary tumor epithelium stained diffusely for BRAF V600E. This observation
supports the conclusion that BRAF mutations are present uniformly throughout the
neoplastic epithelial cells.
Brastianos et al. Page 4
Nat Genet. Author manuscript; available in PMC 2014 August 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tOur whole exome sequencing data of craniopharyngiomas demonstrates that the
adamantinomatous and papillary subtypes have distinct molecular underpinnings, each
principally driven by mutations in a single well-established oncogene – CTNNB1 (beta-
catenin) in the adamantinomatous form and BRAF in the papillary form, independent of age.
These mutations appear to be critical events in the pathogenesis of these tumors for several
reasons. First, the high prevalence of mutations in CTNNB1 and BRAF in
craniopharyngiomas occurs amongst an overall paucity of additional mutations, supporting
that these are likely instrumental to the growth of these tumors. Second, the mutations are
clonal and perfectly segregate with their respective histologic subtypes indicating that these
are defining genetic aberrations. Moreover, the frequency of CTNNB1 mutations and BRAF
mutations are much higher in craniopharyngiomas than in most other tumor types that bear
these mutations.
Given the mutual exclusivity of BRAF and CTNNB1 mutations, immunohistochemistry for
BRAF V600E and beta-catenin could be used to routinely distinguish papillary from
adamantinomatous craniopharyngiomas, and thereby direct patients to appropriate clinical
trials. While agents that target WNT signaling remain in development22,23, the availability
of BRAF inhibitors such as vemurafenib24–29 and dabrafenib30,31 suggests that patients with
papillary craniopharyngiomas could immediately benefit from such targeted therapeutics.
These agents have shown a robust clinical response against BRAF V600E mutant
melanomas25 and hairy cell leukemias32 as well as brain tumors such as pleomorphic
xanthoastrocytoma33,34 and ganglioglioma34,35. Trials of these therapeutics for papillary
craniopharyngiomas should be explored in patients with either residual or recurrent tumor
following surgical resection. Also, BRAF inhibitors could be evaluated as first-line therapy,
prior to surgical resection or radiation therapy.
In summary, our discovery of frequent and clonal mutations in adamantinomatous and
papillary craniopharyngioma in CTNNB1 and BRAF, respectively, offers valuable
opportunities for testing molecularly guided therapeutics for the treatment of these
formidable brain tumors.
ONLINE METHODS
Sample Selection and Preparation
The study was reviewed and approved by the human subjects institutional review boards of
the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Broad Institute of
Harvard and MIT, Boston Children’s Hospital, Johns Hopkins Hospital, Children's Cancer
Hospital Egypt, and Children’s Hospital of Philadelphia. Written informed consent was
obtained from all participants whose tumor samples were subjected to whole-exome
sequencing. Histologic diagnosis was re-confirmed on all samples by a board certified
neuropathologist (S.S.) and representative fresh-frozen and paraffin embedded blocks with
estimated purity of ≥10% were selected. DNA was extracted from tissue shavings of frozen
tissue or 1 mm core punch biopsies (Miltex, cat# 33-31AA-P/25) from FFPE tissue and from
buffy coat preparations of paired blood using standard techniques (QIAGEN, Valencia CA).
The DNA was then quantified using PicoGreen® dye (InVitrogen, Carlsbad CA). Mass
spectrometric genotyping with a well-established 48-SNP panel was used to confirm the
identity of tumor-normal pairs (Sequenom, San Diego CA)36.
Whole Exome Sequencing and Analyses
Whole exome sequencing was performed as previously described15. In brief, DNA was
fragmented by sonication (Covaris Inc., Woburn, MA) to 150 bp and further purified using
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tAgencourt AMPure XP beads. 50 ng size selected DNA was then ligated to specific adaptors
during library preparation (Illumina TruSeq, Illumina Inc, San Diego, CA). Each library was
made with sample specific barcodes, quantified by QPCR (Kapa Biosystems, Inc, Woburn,
MA) and 2 libraries were pooled to a total of 500 ng for exome enrichment using the Agilent
SureSelect hybrid capture kit (Whole Exome_v2 and Whole Exome_v4, 44 Mb; Agilent
Technologies, Santa Clara, CA). Several captures were pooled further and sequenced in one
or more lanes to a final equivalent of 2 exomes per lane on a Hiseq 2500 (Illumina Inc, San
Diego, CA).
Read pairs were aligned to the hg19 reference sequence using the Burrows-Wheeler
Aligner37 and sample reads were de-multiplexed using Picard tools. Data were sorted and
duplicate-marked using Samtools and Picard. Bias in base quality score assignments due to
flowcell, lane, dinucleotide context, and machine cycle were analyzed and recalibrated, and
local realignment around insertions/deletions was achieved using the Genome Analysis
Toolkit (GATK)38,39. Somatic variant calling was performed within the Firehose
environment40 using MuTect13. All sample pairs passed a QC pipeline to test for any tumor/
normal and inter-individual mix-ups by comparing insert-size distribution and copy-number
profile as described previously41.
Somatic mutations and short insertions/deletions were called and post-filtered using
MuTect13 and IndelLocator40,41. These were annotated to genes and compared to events in
the Catalogue of Somatic Mutations in Cancer (COSMIC) using Oncotator, and spurious
calls caused by mis-mapping and other previously identified systematic errors were removed
using an established list of known problematic sites15,40,42,43. MutSig14 was used to
determine the significance of mutated genes. MutSig compares observed mutations against
expected sequence specific, context-specific, tumor-specific and gene specific background
mutation frequencies. Additionally MutSig prioritizes mutations that are positionally
clustered or occur in highly conserved regions40,42,43. We analyzed mutational spectra and
rate across multiple tumor types using previously described methods14.
Mutation clonality analysis
To assess whether mutations are clonal (i.e. present in all cancer cells), we assessed the
cancer cell fraction (CCF) of each mutation, as described in Carter et al44. Mutations for
which the CCF is close to 1 are considered clonal. Those mutations with lower probable
CCFs are considered subclonal. To determine the CCF we first calculated the sample purity
(i.e. the percentage of tumor cells in our sample) by constructing the probability density
function for the allele fractions of mutations. Using that information we then identified a
clonal heterozygous peak at or below 0.5 allele fraction:
where af is the true allele fraction between 0 and 1, alt is the alternate allele counts, ref is the
reference allele counts, m is the index for mutation count44. We assumed local copy number
at each mutation is two for craniopharyngioma and that each tumor has heterozygous clonal
mutations that are sufficient to form a peak45,46. Given these assumptions purity is peak af *
2.
Once we had estimated tumor purity we then estimated the cancer cell fraction (CCF) for
each mutation. The cancer cell fraction is the percentage of tumor cells harboring a given
mutation. Clonal mutations have a true cancer cell fraction of one and subclonal mutations
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thave a true cancer cell fraction of less than one. The observed allele counts correspond to a
probability density of the CCF and this can be estimated with the following equation:44
where CN(m) is the local copy number at the given mutation m, and CCF ranges from 0 to
1. The probability for any allele fraction greater than the maximum CCF allowed was folded
back to a CCF of 1. We assumed again a copy number of two26,27. We also considered the
possibility that the site is homozygous in both copies of the chromosome (loss of
heterozygosity) by multiplying the CCF by 2 in the equation above and chose the solution
with the highest peak probability. The CCF formulation is approximately equivalent to
ABSOLUTE44. The pdfs also provided a direct estimate of the confidence intervals on CCF.
Each mutation was classified as clonal or subclonal based on the probability that the CCF
exceeded 0.80. A probability threshold of 0.5 was used throughout for this classification47.
Validation of Candidate Mutations by Sequenom Genotyping and Snapshot
We validated all of the common mutations in BRAF and CTNNB1 by mass spectrometric
genotyping based on the Sequenom MassARRAY® technology (Sequenom Inc, San Diego,
CA) using a multi-base homogenous Mass-Extend (hME) as previously described35,48. The
complete hME assay list is provided in the supplementary appendix. A second targeted
sequencing platform (SNaPshot genotyping) was performed as previously described to
validate the BRAF V600E (c.1799T>A) mutation in all papillary
craniopharyngiomas33,49,50.
Immunohistochemistry
We performed immunohistochemical studies on five-micrometer-thick whole tissue sections
of formalin-fixed, paraffin-embedded tissue in a Bond 3 automated immunostainer (Leica
Microsystems, Bannockburn, IL, USA) using a primary antibody against BRAF V600E
(clone: VE1, 1:100, Spring Bioscience, Pleasanton, CA) and a primary antibody against
beta-catenin. For BRAF V600E, we deparaffinized the sections on the Leica Bond using
Bond Dewax solution and performed antigen retrieval with an EDTA-based solution (Leica)
at pH 9 and Leica Polymer Refine Kit for DAB (Diaminobenzidine) staining. Appropriate
positive and negative controls were included. Positive staining was characterized by diffuse
and moderate cytoplasmic staining of the tumor cells. We considered isolated nuclear
staining, weak staining of occasional cells, or faint diffuse staining as negative staining. For
beta-catenin (BD pharmigen, cat# 610154, mouse-monoclonal, clone: 14), antigen retrieval
was performed in a pressure cooker in citrate buffer (pH=6.0, 1:1000 dilution) with a 45
minute incubation followed by Dako anti-mouse-HRP for 30 minutes at room temperature.
Cases with nuclear staining (which ranged from low level to high level) were scored as
positive and membranous staining were scored as negative.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Plot of the number of non-synonymous mutations per megabase in craniopharyngiomas in
comparison to a broad range of pediatric and adult tumors. Data for all other tumor types, as
well as the figure design were taken from Lawrence et al14. Each dot in this plot corresponds
to a matched tumor–normal pair. The vertical position indicates the frequency of somatic
mutations in that exome. Tumor types are ordered based on their median non-synonymous
frequency and within each tumor type tumor-normal pairs are ordered from lowest to highest
frequency. The relative proportions of six different possible base-pair substitutions are
indicated in the bottom panel. Craniopharyngioma data are derived from whole exome
sequencing of 15 tumor-normal pairs including 12 adamantinomatous and 3 papillary
craniopharyngioma and marked in red. AML – Acute myelogenous leukemia, Cranio –
Craniopharyngioma, DLBCL – Diffuse large B-cell lymphoma, LUAD – Lung
adenocarcinoma; LUSC – Lung squamous cell carcinoma.
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Mutations in adamantinomatous and papillary craniopharyngiomas. Panel a depicts the
number of mutations per megabase in each of 15 craniopharyngioma whole exome
sequencing data sets (12 adamantinomatous and 3 papillary samples). Specific genes are
listed bearing non-synonymous somatic mutations in genes listed in Cancer Gene Census16.
At the right we show the false discovery rate q-values providing the significance of
mutations in each listed gene. Cancer relevant genes that are not listed in the Cancer Gene
Census are not shown. The q value is an evaluation of whether a gene is significantly
mutated above the expected basal rate of mutation. The q values for BRAF and CTNNB1
are <0.00001. The q values of other genes in the plot are equal to 1. A full list of mutated
Brastianos et al. Page 12
Nat Genet. Author manuscript; available in PMC 2014 August 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tgenes is provided in Supplementary Table 2. Colors indicate the type of genetic change
identified. Only one mutation is indicated even if multiple mutations were found in a
particular gene. The cancer cell fraction (CCF, 0–1.0) for each indicated mutation is shown
in white type in the corresponding box. The allelic fraction for mutations in each sample is
shown in box plots with the median indicated by a red line (the allelic fraction for each
mutation is listed in Supplementary Table 2. For each sample, the relative frequencies of six
different possible base-pair substitutions are presented in the bottom panel. In Panel b,
schematics for CTNNB1 and BRAF indicating the location of identified mutations (11 in
CTNNB1 and 3 in BRAF) are shown.
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Beta-catenin localization is different in adamantinomatous and papillary
craniopharyngiomas. Immunohistochemistry for beta-catenin was performed. In Panel a,
beta-catenin is localized to the cytoplasm and the nucleus in an adamantinomatous
craniopharyngioma. In Panel b, beta catenin is localized to the cell membrane in a papillary
craniopharyngioma. Scale bars, 50 µm. Beta-catenin localization in many samples from the
discovery and validation cohort is reported in Supplementary Table 1.
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tFigure 4.
BRAF and CTNNB1 mutations are clonal in craniopharyngiomas. In Panel a (left), a violin
plot shows the cancer cell fraction (CCF) for BRAF (orange) and CTNNB1 (pink) mutations
in each tumor analyzed with whole exome sequencing. The median CCF of all non-
synonymous somatic mutations for each sample is represented by a black dot. The bar graph
(Panel a, right) shows the computed purity for each sample (see Methods sections); error
bars represent standard error of the mean. In Panel b, we show hematoxylin and eosin
(H&E) staining of adamantinomatous and papillary craniopharyngiomas.
Immunohistochemistry (IHC) shows that adamantinomatous craniopharyngiomas are
negative for BRAF V600E but that there is a diffuse distribution of BRAF V600E mutant
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tprotein in the neoplastic epithelium of papillary craniopharyngiomas. Stromal elements in
the fibrovascular cores of the papillary tumors are negative for the BRAF V600E mutant
protein. Scale bars, 100 µm.
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